Your browser is no longer supported. Please, upgrade your browser.
Settings
GILD Gilead Sciences Inc. daily Stock Chart
GILD [NASD]
Gilead Sciences Inc.
IndexS&P 500 P/E13.15 EPS (ttm)8.80 Insider Own0.50% Shs Outstand1.47B Perf Week-1.47%
Market Cap170.05B Forward P/E10.39 EPS next Y11.13 Insider Trans-18.46% Shs Float1.46B Perf Month0.22%
Income14.21B PEG0.64 EPS next Q2.70 Inst Own85.70% Short Float1.41% Perf Quarter13.50%
Sales27.49B P/S6.19 EPS this Y306.10% Inst Trans0.06% Short Ratio1.89 Perf Half Y13.35%
Book/sh11.55 P/B10.02 EPS next Y2.61% ROA42.70% Target Price124.47 Perf Year24.88%
Cash/sh7.69 P/C15.06 EPS next 5Y20.60% ROE91.30% 52W Range85.64 - 123.37 Perf YTD23.20%
Dividend1.72 P/FCF10.35 EPS past 5Y39.10% ROI44.80% 52W High-6.21% Beta0.79
Dividend %1.49% Quick Ratio2.40 Sales past 5Y28.80% Gross Margin86.00% 52W Low35.11% ATR2.78
Employees7000 Current Ratio2.70 Sales Q/Q51.90% Oper. Margin64.00% RSI (14)50.15 Volatility3.14% 2.04%
OptionableYes Debt/Eq0.72 EPS Q/Q107.50% Profit Margin51.70% Rel Volume2.12 Prev Close113.07
ShortableYes LT Debt/Eq0.69 EarningsJul 28 AMC Payout4.60% Avg Volume10.88M Price115.71
Recom2.00 SMA200.06% SMA500.11% SMA2009.73% Volume23,091,869 Change2.33%
Jul-29-15Reiterated RBC Capital Mkts Outperform $120 → $130
Jul-29-15Reiterated Piper Jaffray Overweight $131 → $134
Jul-29-15Reiterated Oppenheimer Outperform $86 → $120
Jul-29-15Reiterated Needham Buy $120 → $125
Jul-29-15Reiterated Maxim Group Buy $127 → $129
Jul-29-15Reiterated Deutsche Bank Buy $125 → $135
Jul-29-15Reiterated Barclays Overweight $125 → $130
Jul-24-15Reiterated Piper Jaffray Overweight $120 → $131
Jun-23-15Reiterated Argus Buy $130 → $150
May-01-15Reiterated RBC Capital Mkts Outperform $118 → $120
May-01-15Reiterated Piper Jaffray Overweight $116 → $120
Feb-04-15Reiterated RBC Capital Mkts Outperform $125 → $118
Dec-23-14Reiterated Deutsche Bank Buy $142 → $125
Dec-09-14Reiterated Argus Buy $110 → $130
Oct-29-14Reiterated RBC Capital Mkts Outperform $115 → $125
Oct-13-14Reiterated FBR Capital Outperform $125 → $130
Sep-25-14Reiterated Needham Buy $95 → $120
Aug-22-14Reiterated RBC Capital Mkts Outperform $102 → $115
Aug-15-14Initiated FBR Capital Outperform $125
Aug-11-14Reiterated Argus Buy $90 → $110
Jul-29-15 07:51PM  Gilead: the Apple of the Biotech World at The Wall Street Journal
07:45PM  Gilead hepatitis C drugs build road to Japan at bizjournals.com
04:51PM  U.S. stocks end higher as Fed leaves September hike on the table at MarketWatch
02:47PM  Q2 Earnings Season Halftime Report
02:37PM  5 Big Stocks on Traders' Radars -- and What You Should Do With Them Now at TheStreet
02:10PM  Here are all the Boston-area biotechs about to buy or get bought at bizjournals.com
01:52PM  Gilead in Go-Go Mode as Profits, Forecast Impress at Barrons.com
01:27PM  Should Gilead Really Be Rated Underperform? at 24/7 Wall St.
12:33PM  Gilead Sciences, Inc. -- Moody's: Gilead's hepatitis-C sales continue strong streak at Moody's
12:29PM  Gilead Gets Wall Street Love After Q2 Earnings Beat at Investor's Business Daily
12:27PM  4 Stocks, 4 trades: Gilead, Altria & more
12:24PM  Dow adds 100 points as Street awaits Fed statement; earnings eyed at CNBC
11:37AM  Twitter, Yelp sink to 52-week low; Citrix jumps on strong results at MarketWatch
11:02AM  Four Reasons Gilead Can Head Higher at Barrons.com
10:35AM  Cramer -- Gilead Has a Fabulous Quarter, Tons of Merger Opportunities at TheStreet
10:34AM  Gilead Sciences: Here's What A Bull And A Bear Are Saying
10:07AM  Is Biotech a Bubble? Gilead Sciences Doesn't Think So at Barrons.com
09:41AM  Amp Up Your Portfolio With These Biotech Stocks at Motley Fool
09:40AM  Gilead (GILD) Beats on Q2 Earnings, Raises 2015 Outlook - Analyst Blog
09:30AM  Lithia Motors, Qualcomm, Twitter, Gilead and Facebook highlighted as Zacks Bull and Bear of the Day - Press Releases
09:23AM  Cramer's Mad Dash: Hats off to Gilead
09:04AM  Gilead Sciences (GILD) Earnings Report: Q2 2015 Conference Call Transcript at TheStreet
09:00AM  Twitter warning; Anthem gains; MasterCard dollar woes
08:54AM  Top Analyst Upgrades and Downgrades: Amazon, Citrix, Gilead, Sirius XM, 3D Systems, Twitter, Yelp and Many More at 24/7 Wall St.
08:30AM  8 Great Stocks to Own in Retirement at Kiplinger
08:14AM  Focus on Fed; Twitter's big blow; Facebook's politics plunge
07:54AM  Early movers: HLT, ANTM, ETN, TWTR, GSK & more at CNBC
07:46AM  Get ready to cash in on the bottom for commodities at MarketWatch
07:40AM  Top 10 New Stocks to Trade Like Hedge Fund Renaissance Technologies at TheStreet
07:28AM  US STOCKS-U.S. futures higher ahead of Fed statement
03:58AM  Edited Transcript of GILD earnings conference call or presentation 28-Jul-15 8:30pm GMT
Jul-28-15 09:53PM  How a hugely overpriced hepatitis drug helped drive up U.S. health spending at Los Angeles Times
08:07PM  5 Hot Drug Stocks Top IBD's Big Cap Leaders Screen at Investor's Business Daily
06:53PM  Gilead Lifts Sales View As Hep C Drugs Top
06:47PM  Gilead beats Street 2Q forecasts on surge in sales, profit
06:41PM  Gilead hepatitis C sales beat Wall Street, sales outlook raised
06:27PM  Gilead beats Street's 2Q forecasts on surge in sales, profit at San Jose Mercury News
06:00PM  Google, Amazon And Microsoft Curb Spending To Boost Profits
05:58PM  Fast Money Final Trade: GILD, TWTR & YELP
05:51PM  Pricey hepatitis C drugs help Gilead eclipse big sales threshold at bizjournals.com
05:36PM  Twitter Q2 Earnings Turns After-hours Rollercoaster - Analyst Blog
05:20PM  Gilead Sciences Inc. Posts Q2 Results, Able to Beat Earnings, Revenue Estimates - Stocks in the News
05:14PM  Gilead Sciences Inc. Q2 Earnings: Harvoni Delivers Again at Motley Fool
05:12PM  Gilead higher after earnings beat
05:03PM  Express Scripts Raises Guidance as Earnings Top Views at The Wall Street Journal
04:54PM  Twitter soars on strong results; Yelp tanks at MarketWatch
04:54PM  Gilead Tops Estimates in 2Q
04:48PM  Gilead Sciences (GILD) Stock Climbing in After Hours Trading Following Earnings Results at TheStreet
04:34PM  Gilead Q2 Earnings Soar As HCV Shines, HIV Rebounds at Investor's Business Daily
04:30PM  Gilead Sciences Inc Earnings Call scheduled for 4:30 pm ET today
04:28PM  Stocks Pop As China Losses Lessen, Fed Comes Into Focus at Barrons.com
04:23PM  Gilead 2nd-quarter profit increases 32 pct, 2015 outlook raised
04:22PM  Gilead Sales Soar on Hepatitis Drugs at The Wall Street Journal
04:21PM  Gilead Sciences: 'Appears to Be an Awesome Quarter' at Barrons.com
04:16PM  Gilead rallies after earnings beat Wall Street's expectations at MarketWatch
04:15PM  Gilead beats Street 2Q forecasts
04:15PM  Gilead Q2 Earnings: KAPOW! BAM! BOOM! (Yes, That Good) at TheStreet
04:04PM  GILEAD SCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhib
04:03PM  Gilead Profit Tops Estimates as Hepatitis C Drug Sales Surge at Bloomberg
04:02PM  Gilead Sciences Announces Third Quarter 2015 Dividend Business Wire
04:01PM  Gilead Sciences Announces Second Quarter 2015 Financial Results Business Wire
02:31PM  3 stocks for retirees to buy at USA TODAY
01:33PM  Gilead Sciences: How Will the Market React to Slowing U.S. Hep-C Sales? at Barrons.com
01:18PM  Is More M&A On The Way For Large-Cap Biotechs?
01:13PM  5 Health Care Stocks to Trade for Gains -- Must-See Charts at TheStreet
12:59PM  Halftime's hottest trades: Earnings plays
12:58PM  Top trades for the 2nd half: ESRX, MA & GILD
10:35AM  Biogens 2Q15 Earnings Beat Wall Street Estimates
10:02AM  Wait, Will Allergan Really Buy Biogen or Amgen? at Barrons.com
09:30AM  The Zacks Analyst Blog Highlights: Gilead Sciences, AbbVie, Merck, Achillion Pharmaceuticals and Express Scripts - Press Releases
08:00AM  Biotech darling Gilead to pale in comparison to previous quarters: Estimize
07:42AM  Are These 2 Big Pharmas Really Buyout Candidates? at Motley Fool
07:07AM  Q2 2015 Gilead Sciences Inc Earnings Release - 4:05 pm ET
07:03AM  3 Big Biotech Buybacks That Investors Should Love at Motley Fool
06:31AM  Merck Targets Toughest Cases for Foothold in Hepatitis C Market at Bloomberg
Jul-27-15 08:15PM  Fed Meeting, Twitter Earnings, Consumer Data in Focus Tuesday at TheStreet
07:03PM  3 Stocks for Retirees to Buy at Motley Fool
06:46PM  Which Big-Cap Stocks Are Defying Market Pressure? at Investor's Business Daily
05:16PM  Gilead Sciences: Sure, It's Hep-C But It's Not Just Hep-C at Barrons.com
04:30PM  Gilead Announces Executive Promotions Business Wire
04:30PM  Cramer -- Twitter Has Short-Term Problems; Gilead's 'Problem' Is Too Much Cash at TheStreet
04:12PM  Wall Street's Best Think Gilead Will Continue To Outperform The Market
03:24PM  Is Gilead Sciences About to Make an Acquisition?
02:52PM  What to Watch in the Day Ahead - Tuesday, July 28 Reuters
02:37PM  The Incredible Gilead Faces Its Moment of Truth
12:42PM  Gilead Can Soothe Biotech Investor Fears with Great 2Q Earnings at TheStreet
10:30AM  5 Stocks to Watch for this Week 7/27
10:06AM  Whats Gileads Deal? Cash Burns Hole in Investors Pockets at Bloomberg
07:57AM  Short Sellers Back Off Major Biotechs at 24/7 Wall St.
Jul-26-15 09:40PM  This Healthcare Fund Thinks Large-Caps Are The Best Way To Go at Insider Monkey
05:21PM  The Only Six Stocks That Matter at The Wall Street Journal
12:15PM  [video]What to Watch in the Week Ahead: Twitter, Facebook Earnings, GDP at TheStreet
10:21AM  BioPharma Earnings Bracing for Merck, Pfizer, Amgen, Gilead at 24/7 Wall St.
Jul-25-15 07:07AM  1 ETF Thats Crushing Even Warren Buffett at Motley Fool
02:52AM  Global Contrarian Sees Value All Around at Barrons.com
Jul-24-15 06:00PM  Cramer: Market about Chinese pain & Fed worries - not ear...
03:30PM  Gilead (GILD) to Report Q2 Earnings: Surprise in the Cards? - Analyst Blog
02:30PM  Street Talk: SCTY, V, BIDU & GILD
02:09PM  Biogen: Run Lola Run? at Barrons.com
12:45PM  Countdown to health care earnings
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical need in North America, South America, Europe, and the Asia-Pacific. The company's products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver disease. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaborations with Bristol-Myers Squibb Company, Janssen R&D Ireland, and Japan Tobacco Inc. to develop and commercialize various products. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BISCHOFBERGER NORBERT WEVP, R&D and CSOJul 15Option Exercise21.5870,0001,510,250235,168Jul 17 03:57 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJul 15Sale118.2066,2617,832,152168,907Jul 17 03:57 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJul 07Sale119.393,739446,400165,168Jul 17 03:57 PM
Carter Paul RutherfordEVP Commercial OpsJul 01Option Exercise26.993,00080,97050,632Jul 06 04:00 PM
Alton Gregg HEVP, Corp & Med AffairsJul 01Option Exercise23.7615,000356,325156,422Jul 06 04:01 PM
MARTIN JOHN CChairman and CEOJul 01Option Exercise14.50150,0002,175,3754,364,492Jul 06 04:02 PM
Carter Paul RutherfordEVP Commercial OpsJul 01Sale118.243,000354,72947,632Jul 06 04:00 PM
Alton Gregg HEVP, Corp & Med AffairsJul 01Sale116.7317,0001,984,446139,422Jul 06 04:01 PM
MARTIN JOHN CChairman and CEOJul 01Sale116.46150,00017,469,6614,214,492Jul 06 04:02 PM
Cogan John FrancisDirectorJun 26Option Exercise14.3412,000172,08056,309Jun 30 07:32 PM
Cogan John FrancisDirectorJun 26Sale120.1327,0003,243,42144,309Jun 30 07:32 PM
Carter Paul RutherfordEVP Commercial OpsJun 18Option Exercise26.9910,000269,90057,632Jun 22 04:17 PM
Carter Paul RutherfordEVP Commercial OpsJun 18Sale120.0010,0001,200,02547,632Jun 22 04:17 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJun 15Option Exercise21.5870,0001,510,250235,168Jun 17 07:25 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJun 15Sale117.6770,0008,237,002165,168Jun 17 07:25 PM
MILLIGAN JOHN FPresident and COOJun 08Option Exercise14.50100,0001,450,2501,129,108Jun 10 01:03 PM
MILLIGAN JOHN FPresident and COOJun 08Sale114.05100,00011,405,4131,029,108Jun 10 01:03 PM
Carter Paul RutherfordEVP Commercial OpsJun 01Option Exercise34.713,000104,12050,632Jun 03 06:07 PM
MARTIN JOHN CChairman and CEOJun 01Option Exercise14.50150,0002,175,3754,405,876Jun 03 06:07 PM
Alton Gregg HEVP, Corp & Med AffairsJun 01Option Exercise23.7115,000355,647158,422Jun 03 06:07 PM
MARTIN JOHN CChairman and CEOJun 01Sale113.95150,00017,092,3444,255,876Jun 03 06:07 PM
Alton Gregg HEVP, Corp & Med AffairsJun 01Sale113.6417,0001,931,891141,422Jun 03 06:07 PM
Carter Paul RutherfordEVP Commercial OpsJun 01Sale113.093,000339,27847,632Jun 03 06:07 PM
Carter Paul RutherfordEVP Commercial OpsMay 15Option Exercise67.786,000406,68753,632May 19 07:24 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOMay 15Option Exercise21.3470,0001,493,550235,168May 19 07:25 PM
Alton Gregg HEVP, Corp & Med AffairsMay 15Option Exercise19.2025,000479,947168,422May 19 07:25 PM
Carter Paul RutherfordEVP Commercial OpsMay 15Sale110.006,000660,02047,632May 19 07:24 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOMay 15Sale109.4570,0007,661,533165,168May 19 07:25 PM
Alton Gregg HEVP, Corp & Med AffairsMay 15Sale110.0125,0002,750,210143,422May 19 07:25 PM
Carter Paul RutherfordEVP Commercial OpsMay 10Option Exercise0.005,000050,439May 12 06:02 PM
MILLIGAN JOHN FPresident and COOMay 07Option Exercise14.50100,0001,450,2501,129,108May 11 08:24 PM
MILLIGAN JOHN FPresident and COOMay 07Sale101.00100,00010,100,1621,029,108May 11 08:24 PM
Whitley Richard JamesDirectorMay 05Option Exercise19.6321,720426,36437,361May 07 05:14 PM
Alton Gregg HEVP, Corp & Med AffairsMay 01Option Exercise19.0910,000190,850155,422May 05 07:38 PM
Carter Paul RutherfordEVP Commercial OpsMay 01Option Exercise80.652,000161,30047,439May 05 04:23 PM
MARTIN JOHN CChairman and CEOMay 01Option Exercise14.50150,0002,175,3754,405,876May 05 05:47 PM
Washington Robin LEVP, CFOMay 01Option Exercise29.7016,842500,13044,566May 05 07:38 PM
MARTIN JOHN CChairman and CEOMay 01Sale104.95150,00015,742,4914,255,876May 05 05:47 PM
Carter Paul RutherfordEVP Commercial OpsMay 01Sale103.182,000206,36545,439May 05 04:23 PM
Alton Gregg HEVP, Corp & Med AffairsMay 01Sale104.0712,0001,248,871143,422May 05 07:38 PM
Washington Robin LEVP, CFOMay 01Sale105.0616,8421,769,40527,724May 05 07:38 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOApr 15Option Exercise20.7470,0001,451,800235,168Apr 17 02:23 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOApr 15Sale103.8470,0007,268,627165,168Apr 17 02:23 PM
Alton Gregg HEVP, Corp & Med AffairsApr 08Option Exercise19.095,00095,425150,422Apr 09 04:40 PM
Carter Paul RutherfordEVP Commercial OpsApr 08Option Exercise80.651,00080,65046,439Apr 09 04:40 PM
Alton Gregg HEVP, Corp & Med AffairsApr 08Sale100.005,000500,000145,422Apr 09 04:40 PM
Carter Paul RutherfordEVP Commercial OpsApr 08Sale100.001,000100,00045,439Apr 09 04:40 PM
Carter Paul RutherfordEVP Commercial OpsApr 01Option Exercise80.651,00080,65046,439Apr 03 05:24 PM
Alton Gregg HEVP, Corp & Med AffairsApr 01Option Exercise19.095,00095,425152,422Apr 03 05:24 PM
MARTIN JOHN CChairman and CEOApr 01Option Exercise14.50150,0002,175,3754,405,876Apr 03 05:24 PM
Alton Gregg HEVP, Corp & Med AffairsApr 01Sale96.537,000675,715145,422Apr 03 05:24 PM
Carter Paul RutherfordEVP Commercial OpsApr 01Sale98.041,00098,04445,439Apr 03 05:24 PM
MARTIN JOHN CChairman and CEOApr 01Sale96.74150,00014,511,4634,255,876Apr 03 05:24 PM
Whitley Richard JamesDirectorMar 02Option Exercise26.995,000134,95020,641Mar 03 04:12 PM
Alton Gregg HEVP, Corp & Med AffairsMar 02Option Exercise19.0910,000190,850159,422Mar 04 07:49 PM
MARTIN JOHN CChairman and CEOMar 02Option Exercise14.50150,0002,175,3754,405,876Mar 04 07:48 PM
Carter Paul RutherfordEVP Commercial OpsMar 02Option Exercise80.652,000161,30047,439Mar 04 07:49 PM
Carter Paul RutherfordEVP Commercial OpsMar 02Sale104.182,000208,36445,439Mar 04 07:49 PM
MARTIN JOHN CChairman and CEOMar 02Sale103.51150,00015,526,2454,255,876Mar 04 07:48 PM
Alton Gregg HEVP, Corp & Med AffairsMar 02Sale103.6312,0001,243,615147,422Mar 04 07:49 PM
Whitley Richard JamesDirectorMar 02Sale103.435,000517,13615,641Mar 03 04:12 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOFeb 17Option Exercise16.4070,0001,147,650235,168Feb 19 06:42 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOFeb 17Sale103.0170,0007,210,740165,168Feb 19 06:42 PM
WOLD OLSEN PERDirectorFeb 06Buy99.9210,000999,15088,173Feb 10 04:30 PM
MARTIN JOHN CChairman and CEOFeb 02Option Exercise14.50150,0002,175,3754,272,987Feb 04 08:15 PM
Washington Robin LEVP, CFOFeb 02Option Exercise25.1433,192834,58683,024Feb 04 08:52 PM
Alton Gregg HEVP, Corp & Med AffairsFeb 02Option Exercise19.0910,000190,850123,694Feb 04 08:51 PM
Carter Paul RutherfordEVP Commercial OpsFeb 02Option Exercise80.652,000161,30036,308Feb 04 08:52 PM
Whitley Richard JamesDirectorFeb 02Option Exercise26.995,000134,95020,641Feb 04 04:04 PM
MARTIN JOHN CChairman and CEOFeb 02Sale105.43150,00015,815,2494,122,987Feb 04 08:15 PM
Washington Robin LEVP, CFOFeb 02Sale105.3833,1923,497,66249,832Feb 04 08:52 PM
Alton Gregg HEVP, Corp & Med AffairsFeb 02Sale105.7312,0001,268,719111,694Feb 04 08:51 PM
Carter Paul RutherfordEVP Commercial OpsFeb 02Sale106.152,000212,31034,308Feb 04 08:52 PM
Whitley Richard JamesDirectorFeb 02Sale105.675,000528,35815,641Feb 04 04:04 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJan 15Option Exercise16.4070,0001,147,650189,302Jan 20 12:46 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJan 15Sale98.4770,0006,893,083119,302Jan 20 12:46 PM
Carter Paul RutherfordEVP Commercial OpsJan 08Option Exercise36.721,00036,72035,308Jan 12 03:55 PM
Carter Paul RutherfordEVP Commercial OpsJan 08Sale100.881,000100,88134,308Jan 12 03:55 PM
MARTIN JOHN CChairman and CEOJan 05Sale96.651009,6654,122,987Jan 06 04:20 PM
Carter Paul RutherfordEVP Commercial OpsJan 02Option Exercise40.561,00040,56035,308Jan 06 04:21 PM
MARTIN JOHN CChairman and CEOJan 02Option Exercise14.50150,0002,175,3754,272,987Jan 06 04:20 PM
Whitley Richard JamesDirectorJan 02Option Exercise26.995,000134,95020,641Jan 06 02:12 PM
Alton Gregg HEVP, Corp & Med AffairsJan 02Option Exercise19.095,00095,425120,694Jan 06 04:20 PM
Whitley Richard JamesDirectorJan 02Sale95.225,000476,10015,641Jan 06 02:12 PM
MARTIN JOHN CChairman and CEOJan 02Sale95.11149,90014,257,7224,123,087Jan 06 04:20 PM
Alton Gregg HEVP, Corp & Med AffairsJan 02Sale95.177,000666,192113,694Jan 06 04:20 PM
Carter Paul RutherfordEVP Commercial OpsJan 02Sale95.051,00095,05034,308Jan 06 04:21 PM
Cogan John FrancisDirectorDec 22Option Exercise14.3426,000372,77568,405Dec 24 12:58 PM
Cogan John FrancisDirectorDec 22Sale95.0326,0002,470,75542,405Dec 24 12:58 PM
MILLIGAN JOHN FPresident and COODec 08Option Exercise8.01146,8231,175,3181,120,871Dec 10 05:32 PM
MILLIGAN JOHN FPresident and COODec 08Sale106.26146,82315,601,122974,048Dec 10 05:32 PM
MARTIN JOHN CChairman and CEODec 01Option Exercise8.01140,6331,125,7674,263,620Dec 03 07:13 PM
Carter Paul RutherfordEVP Commercial OpsDec 01Option Exercise40.562,00081,12036,308Dec 03 07:14 PM
Alton Gregg HEVP, Corp & Med AffairsDec 01Option Exercise24.2931,000752,947149,694Dec 03 07:13 PM
Whitley Richard JamesDirectorDec 01Option Exercise26.995,000134,95020,641Dec 03 03:46 PM
Carter Paul RutherfordEVP Commercial OpsDec 01Sale100.022,000200,03134,308Dec 03 07:14 PM
MARTIN JOHN CChairman and CEODec 01Sale100.72140,63314,164,8294,122,987Dec 03 07:13 PM
Alton Gregg HEVP, Corp & Med AffairsDec 01Sale100.7933,0003,325,922116,694Dec 03 07:13 PM
Whitley Richard JamesDirectorDec 01Sale100.195,000500,96915,641Dec 03 03:46 PM
Cogan John FrancisDirectorNov 21Option Exercise14.3425,000358,43867,405Nov 25 04:10 PM